Besides being the single most preventable cause of significant morbidity and an important cause of death in the general population, tobacco smoking has been associated with adverse effects on the skin. Smoke-induced premature skin ageing has attracted the attention of the medical community, while only recently an observational study has indicated a significant relationship between smoking and baldness. The mechanisms by which smoking causes hair loss are multifactorial and are probably related to effects of cigarette smoke on the microvasculature of the dermal hair papilla, smoke genotoxicants causing damage to DNA of the hair follicle, smoke-induced imbalance in the follicular protease/antiprotease systems controlling tissue remodeling during the hair growth cycle, pro-oxidant effects of smoking leading to the release of pro-inflammatory cytokines resulting in follicular micro-inflammation and fibrosis and finally increased hydroxylation of oestradiol as well as inhibition of the enzyme aromatase creating a relative hypo-oestrogenic state. In view of the psychological impact of androgenetic alopecia on affected men and women, increasing public awareness of the association between smoking and hair loss offers an opportunity for health education against smoking that may be more effective than the link between smoking and facial wrinkles or grey hair, since the latter can be effectively counteracted by current aesthetic dermatologic procedures, while treatment options for androgenetic alopecia are limited.

Keywords:
Tobacco smoking, Hair loss, Psychological effects of androgenetic alopecia, Public awareness, Health education against smoking
1.
Hayakawa K, Shimizu T, Ohba Y, et al: Intrapair differences of physical aging and longevity in identical twins. Acta Genet Med Gemellol 1992;41:177–185.
2.
Smith JB, Fenske NA: Cutaneous manifestations and consequences of smoking. J Am Acad Dermatol 1996;34:717–732.
3.
Solly S: Clinical lectures on paralysis. Lancet 1856;ii:641–643.
4.
Daniell HW: Smoker’s wrinkles: A study in the epidemiology of ‘crow’s feet’. Ann Intern Med 1971;75:873–880.
5.
Ippen M, Ippen H: Approaches to a prophylaxis of skin ageing. J Soc Cosmet Chemists 1965;16:305–308.
6.
Weiss W: Smoker’s wrinkles. JAMA 1973;226:788.
7.
Model D: Smokers face: An underrated clinical sign? BMJ 1985;291:1760–1762.
8.
Kadunce DP, Burr R, Gress R, et al: Cigarette smoking: Risk factor for premature facial wrinkling. Ann Intern med 1991;114:840–844.
9.
Grandy D, Ernster V: Does cigarette smoking make you ugly and old? Am J Epidemiol 1992;135:839–842.
10.
Davis BE, Koh HK: Faces going up in smoke. Arch Dermatol 1992;128:1106–1107.
11.
Ernster VL, Grady D, Milke R, et al: Facial wrinkling in men and women, by smoking status. Am J Public Health 1995;85:78–82.
12.
Wolf R, Lo Schiavo A, Ruocco V: Smoking out the skin. J Appl Cosmetol 1995;13:1–14.
13.
Frances C, Boisnic S, Hartmann DJ: Changes in elastic tissue of the nun-sun-exposed skin of cigarette smokers. Br J Dermatol 1991;125:43–47.
14.
Boyd AS, Stasko T, King LE, et al: Cigarette smoking-associated elastotic changes in the skin. J Am Acad Dermatol 1999;41:23–26.
15.
Demierre MF, Brooks D, Koh HK, Geller AC: Public knowledge, awareness, and perceptions of the association between skin aging and smoking. J Am Acad Dermatol 1999;41:27–30.
16.
Tur E, Yosipovitch G, Oren-Vulfs S: Chronic and acute effects of cigarette smoking on skin blood flow. Angiology 1992;328–335.
17.
Raitio A, Risteli J, Väjäkangas K, Oikarinen A: Evidence of disturbed collagen metabolism in smokers – A possible etiologic factor for accelerated skin aging. J Invest Dermatol 2000;114:822.
18.
Laurent P, Janoff A, Kagan HM: Cigarette smoke blocks cross-linking of elastin in vitro. Annu Rev Respir Dis 1983;127:189–194.
19.
Joffe I: Cigarette smoking and facial wrinkling. Ann Intern Med 1991;115:659.
20.
Weber C, Erl W, Weber K, Weber PC: Increased adhesiveness of isolated monocytes to endothelium is prevented by vitamin C intake in smokers. Circulation 1996;93:1488–1492.
21.
Frances C: Smoking and the skin. Int J Dermatol 1992;31:779–780.
22.
Osawa Y, Tochigi B, Tochigi M, et al: Aromatase inhibitors in cigarette smoke, tobacco leaves and other plants. J Enzyme Inhib 1990;4:187–200.
23.
Weitz JL, Crowley KA, Landman SL, et al: Increased neutrophil elastase activity in cigarette smokers. Ann Intern Med 1987;107:680–682.
24.
Lahmann C, Bergemann J, Harrison G, Young AR: Matrix metalloproteinase-1 and skin ageing in smokers. Lancet 2001;357:935–936.
25.
Yin L, Morita A, Tsuji T: Alterations of extracellular matrix induced by tobacco smoke extract. Arch Dermatol Res 2000;292:188–194.
26.
Mosley JG, Gibbs CC: Premature grey hair and hair loss among smokers: A new opportunity for health education? BMJ 1996;313:1616.
27.
Dardour JC, Pugash E, Aziza R: The one-stage preauricular flap for male pattern baldness: Long-term results and risk factors. Plast Reconstr Surg 1988;81:907–912.
28.
Haley NJ, Hoffmann D: Analysis for nicotine and cotinine in hair to determine cigarette smoker status. Clin Chem 1985;31:1598–1600.
29.
Liu CS, Kao SH, Wei YH: Smoking-associated mitochondrial DNA mutations in human hair follicles. Environ Mol Mutagen 1997;30:47–55.
30.
D’Agostini F, Balansky R, Pesce C, et al: Induction of alopecia in mice exposed to cigarette smoking. Toxicol Lett 2000;114:117–123.
31.
Paus R, Krejci-Papa N, Li L, et al: Correlation of proteolytic activities of organ cultured intact mouse skin with defined hair cycle stages. J Dermatol Sci 1994;7:202–209.
32.
Philpott MP, Sander DA, Bowen J, Kealey T: Effects of interleukins, colony stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: A possible role for interleukin-1 and tumour necrosis factor-α in alopecia areata. Br J Dermatol 1996;135:942–948.
33.
Mahé YF, Michelet JF, Billoni N, et al: Androgenetic alopecia and microinflammation. Int J Dermatol 2000;39:576–584.
34.
Kaufman KD: Androgen metabolism as it affects hair growth in androgenetic alopecia. Dermatol Clin 1996;14:697–711.
35.
Trüeb RM: Molecular mechanisms in androgenetic alopecia. Exp Gerontol 2002;37:981–990.
36.
Moehrle M, Dennenmoser B, Schlagenhauff B, et al: High prevalence of seborrhoeic dermatitis on the face and scalp of mountain guides. Dermatology 2000;201:146–147.
37.
Piérard GE, Piérard-Franchimont C, Nikkels-Tassoudji N, et al: Improvement in the inflammatory aspect of androgenetic alopecia: A pilot study with an antimicrobial lotion. J Dermatol Treat 1996;7:153–157.
38.
Arck PC, Handjiski B, Hagen E, et al: Indications for a ‘brain-hair follicle axis (BHA)’: Inhibition of keratinocyte proliferation and up-regulation of keratinocyte apoptosis in telogen hair follicles by stress and substance P. FASEB J 2001;15:2536–2538.
39.
Willimann B, Trüeb RM: Hair pain (trichodynia): Frequency and relationship to hair loss and patient gender. Dermatology, in press.
40.
Cash TF: The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol 1992;26:926–931.
41.
Cash TF, Price VH, Savin RC: Psychological effects of androgenetic alopecia on women: Comparisons with balding men and with female control subjects. J Am Acad Dermatol 1993;29:568–575.
42.
Price VH: Treatment of hair loss. N Engl J Med 1999;341:964–973.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.